About bioatla inc - BCAB
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
BCAB At a Glance
BioAtla, Inc.
11085 Torreyana Road
San Diego, California 92121
| Phone | 1-858-558-0708 | Revenue | 2.00M | |
| Industry | Biotechnology | Net Income | -59,607,000.00 | |
| Sector | Health Technology | Employees | 41 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
BCAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.698 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.628 |
| Enterprise Value to Sales | 18.31 |
| Total Debt to Enterprise Value | 0.282 |
BCAB Efficiency
| Revenue/Employee | 48,780.488 |
| Income Per Employee | -1,453,829.268 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.059 |
BCAB Liquidity
| Current Ratio | 0.366 |
| Quick Ratio | 0.366 |
| Cash Ratio | 0.325 |
BCAB Profitability
| Gross Margin | 81.35 |
| Operating Margin | -2,935.25 |
| Pretax Margin | -2,980.35 |
| Net Margin | -2,980.35 |
| Return on Assets | -176.844 |
| Return on Equity | N/A |
| Return on Total Capital | 230.615 |
| Return on Invested Capital | N/A |
BCAB Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -40.012 |
| Total Debt to Total Assets | 68.993 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -18.466 |